This session highlighted where prediction fails today, the mechanistic gaps that limit current approaches, and how human NAMs can help close that gap. It also emphasised the key insights teams need to move from reactive findings to more proactive, informed decision-making.
To deliver therapeutics effectively to the nasal and pulmonary regions, developers must address the physiological barriers in these tissues. This webinar covers how formulation techniques and early in vitro toxicology work together to accelerate development and reduce risk.
In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.
In ImmuBYTES Session 3, “Looking Beyond Baseline Deviations for Lung and Immune Safety,” Prof. Victoria Hutter (CSO & Co-founder) highlighted how subtle changes in macrophage morphology can uncover early immune and lung effects.
Early detection of pulmonary ADC toxicity using ImmuONE’s morph_ONE™ high-content imaging assay of alveolar macrophages to improve safety and efficacy in ADC drug development.
Immune cells are reshaping inhalation toxicology by offering deeper insights into respiratory and systemic effects of tested compounds. In the second ImmuBYTES webinar, ‘Immune cells
A UK biotech start-up with a 3D human lung model that provides an alternative to animal testing has raised a further £600,000 from the Midlands
Welcome to ImmuBYTES, a new series designed to deliver bite-sized insights into cutting-edge tools in cell-based research and toxicology to drive innovation and discovery.
In our recent ImmuBYTES webinar, we delved into the fascinating world of Cell Painting, a high-content imaging assay (HCIA) that transforms cellular morphology into a rich source of data.